Literature DB >> 4802524

Malignant hyperpyrexia myopathy.

D G Harriman, D W Sumner, F R Ellis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4802524

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


× No keyword cloud information.
  15 in total

1.  Evaluation of creatinine phosphokinase in screening patients for malignant hyperpyrexia.

Authors:  F R Ellis; I M Clarke; M Modgill; S Currie; D G Harriman
Journal:  Br Med J       Date:  1975-08-30

2.  [Death from malignant hyperthermia during anaesthesia (author's transl)].

Authors:  I Bayer-Kristensen; E Reske-Nielsen; A Harmsen
Journal:  Z Rechtsmed       Date:  1975-11-11

3.  Malignant hyperpyrexia: a rare cause of postoperative death.

Authors:  R J Prescott; S P Roberts; G Williams
Journal:  J Clin Pathol       Date:  1992-04       Impact factor: 3.411

4.  Hypertrophy of the branchial muscles. A case with unusual features.

Authors:  C D Lambert; J R Young
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-08       Impact factor: 10.154

Review 5.  Etiopathogenetic defect of malignant hyperthermia: hypersensitive calcium-release channel of skeletal muscle sarcoplasmic reticulum.

Authors:  P J O'Brien
Journal:  Vet Res Commun       Date:  1987       Impact factor: 2.459

6.  Malignant hyperpyrexia induced by nitrous oxide and treated with dexamethasone.

Authors:  F R Ellis; I M Clarke; T N Appleyard; R C Dinsdale
Journal:  Br Med J       Date:  1974-11-02

7.  Editorial: New causes of malignant hyperpyrexia.

Authors: 
Journal:  Br Med J       Date:  1974-11-30

8.  Malignant hyperthermia: a pharmacogenetic disease of skeletal and cardiac muscle.

Authors:  B A Britt
Journal:  Anesth Prog       Date:  1974 Jul-Aug

9.  The caffeine test of isolated human muscle in relation to malignant hyperthermia.

Authors:  W Kalow; B A Britt; A Richter
Journal:  Can Anaesth Soc J       Date:  1977-11

Review 10.  Adverse effects of drugs on muscle.

Authors:  F L Mastaglia
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.